Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Transplant ; 30(9): 1002-9, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27293140

RESUMO

INTRODUCTION: Thrombosis of the pancreas after transplantation is the most common cause of relaparotomy and resultant graft loss. There is currently no standard protocol consistently proven to prevent thrombosis following transplantation. Our objective was to determine whether our protocol of post-operative low-dose intravenous (IV) heparin infusion would prevent graft thrombosis without additional complications in our patients. METHODS: A total of 66 simultaneous pancreas kidney (SPK) transplants were performed at our institution from 2004 to 2014. Patients were divided into 2 retrospective cohort groups. Group 1 patients received only acetylsalicylic acid (ASA) 81 mg/d started on post-operative day 1. Group 2 patients received IV heparin infusion beginning in the recovery room at a rate of 500 IU/h for the first 24 hours, reduced by 100 IU/h every day to stop on day 5, and then received ASA 81 mg/d afterward. Outcome and complication rates were compared between the two groups for 5 years post-transplant. RESULTS: We observed a significant reduction in graft thrombosis and graft loss with (0/29) patients in the heparin group vs (7/33) 25.7% from the non-heparin (P<.01) with no differences in complication rates. CONCLUSIONS: We present a heparin infusion protocol which may help prevent graft thrombosis and graft loss in SPK transplantation.


Assuntos
Rejeição de Enxerto/complicações , Heparina/administração & dosagem , Transplante de Rim/efeitos adversos , Transplante de Pâncreas/efeitos adversos , Complicações Pós-Operatórias , Trombose/prevenção & controle , Adulto , Canadá/epidemiologia , Relação Dose-Resposta a Droga , Feminino , Fibrinolíticos/administração & dosagem , Seguimentos , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/epidemiologia , Sobrevivência de Enxerto , Humanos , Incidência , Infusões Intravenosas , Masculino , Estudos Retrospectivos , Fatores de Risco , Trombose/epidemiologia , Trombose/etiologia , Fatores de Tempo
2.
Arch Pathol Lab Med ; 130(2): 205-8, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16454564

RESUMO

Interdigitating dendritic cell sarcoma is an extremely rare malignancy derived from antigen-presenting cells. Dendritic cells constitute a heterogeneous group of cells, which includes Langerhans cells, dermal dendrocytes, follicular dendritic cells, and interdigitating dendritic cells present in lymphoid and nonlymphoid organs. We report the case of a 36-year-old woman who presented with epigastric pain, projectile vomiting, and significant weight loss. Upper gastrointestinal endoscopy showed a duodenal lesion; a biopsy of the lesion was taken and was diagnosed as sarcoma. She underwent a Whipple procedure. A final diagnosis of interdigitating dendritic cell sarcoma was made, with liver and peripancreatic lymph node involvement. The patient deteriorated rapidly and died 4 months later. Although interdigitating dendritic cell sarcoma of the duodenum is extremely rare, we think it should be included in the differential diagnosis of unusual spindle cell tumors with a rich lymphocytic infiltrate.


Assuntos
Células Dendríticas/patologia , Neoplasias Duodenais/patologia , Sarcoma/patologia , Adulto , Diagnóstico Diferencial , Neoplasias Duodenais/cirurgia , Evolução Fatal , Feminino , Humanos , Neoplasias Hepáticas/secundário , Linfonodos/patologia , Sarcoma/diagnóstico , Sarcoma/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...